Approved: 4 Oct 2017. Last amended: 4 Oct 2017.

8.1 Cytotoxic drugs

Not currently included in Joint Formulary

8.2 Drugs affecting the immune response

Not currently included in Joint Formulary

8.3 Sex hormones and hormone antagonists in malignant disease

8.3.1 Oestrogens

Not currently included in Joint Formulary

8.3.2 Progrestogens

Not currently included in Joint Formulary

8.3.3 Androgens

Not currently included in Joint Formulary

8.3.4 Hormone antagonists

8.3.4.1 Breast Cancer

Not currently included in Joint Formulary

8.3.4.2 Gonadorelin analogues

Recommended

  • Triptorelin (Decapeptyl® SR)

    3mg, 11.25mg, 22.5mg (22.5mg IM 6 monthly injection preferred in Primary Care)

  • Alternative

  • Leuprorelin (Prostap®)

    3.75mg, 11.25mg

  • Goserelin (Zoladex®)

    3.6mg, 10.8mg

  • 8.3.4.3 Anti-androgens

    Recommended

  • Bicalutamide

  • Alternative

  • Cyproterone

  • Specific Indication

  • Abiraterone

    castration-resistant metastatic prostate cancer, as per NICE TA259

  • 8.3.4.4 Gonadotrophin-releasing hormone antagonists

  • Degarelix

    Advanced hormone-dependent prostate cancer in people with spinal metastases, as per NICE TA404

  • 8.3.4.5 Somatostatin analogues

    Not currently included in Joint Formulary

    BEST CARE FOR EVERYONE